Acer Therapeutics Compliant with All Nasdaq Listing Criteria

Rhea-AI Summary

Acer Therapeutics Inc. (Nasdaq: ACER) has confirmed that it has regained compliance with Nasdaq's $35 million market value requirement for continued listing on the Nasdaq Capital Market. This notification means the previously scheduled hearing before the Nasdaq Hearings Panel has been canceled. Acer focuses on developing therapies for rare and life-threatening diseases, with its product OLPRUVA™ approved for treating urea cycle disorders. The company also has several investigational candidates in its pipeline for various serious conditions.

Positive

• Acer has regained compliance with Nasdaq's $35 million market value requirement.
• The scheduled hearing for Nasdaq compliance has been canceled.

Negative

• None.

NEWTON, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the $35 million market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing on The Nasdaq Capital Market. Accordingly, the listing matter is now closed and the previously-scheduled hearing before the Nasdaq Hearings Panel has been cancelled.

About Acer Therapeutics
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. In the U.S., OLPRUVA™ (sodium phenylbutyrate) is approved for the treatment of urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). Acer is also advancing a pipeline of investigational product candidates for rare and life-threatening diseases, including: OLPRUVA™ (sodium phenylbutyrate) for treatment of various other inborn errors of metabolism, including Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS) and Post-traumatic Stress Disorder (PTSD); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, Zika, dengue, Ebola and COVID-19. For more information, visit www.acertx.com.

Acer Contacts
Corporate contact:
Jim DeNike
Acer Therapeutics Inc.
jdenike@acertx.com
+1-844-902-6100

Investor contact:
Nick Colangelo
Gilmartin Group
nick@gilmartinIR.com
+1-332-895-3226

FAQ

What does the recent Nasdaq compliance notification mean for ACER?

Acer Therapeutics has regained compliance with Nasdaq's $35 million market value requirement, which allows it to remain listed on the Nasdaq Capital Market.

Is Acer Therapeutics still listed on the Nasdaq?

Yes, Acer Therapeutics remains listed on the Nasdaq Capital Market after meeting compliance requirements.

What is Acer Therapeutics focused on?

Acer Therapeutics is focused on developing treatments for serious rare and life-threatening diseases.

What products are associated with Acer Therapeutics?

Acer is known for OLPRUVA™, which treats urea cycle disorders, and it has ongoing developments for several investigational candidates.